Michael Aviram
The Lipid Research Laboratory
Technion-Israel Institute of Technology Faculty of Medicine
The Rappaport Family Institute for Research in the Medical Sciences
Rambam Medical Center
Israel
Name/email consistency: high
- Consumption of polyphenolic-rich beverages (mostly pomegranate and black currant juices) by healthy subjects for a short term increased serum antioxidant status, and the serum's ability to attenuate macrophage cholesterol accumulation. Rosenblat, M., Volkova, N., Attias, J., Mahamid, R., Aviram, M. Food. Funct (2010)
- Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins. Aviram, M., Volkova, N., Coleman, R., Dreher, M., Reddy, M.K., Ferreira, D., Rosenblat, M. J. Agric. Food Chem. (2008)
- Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Aviram, M., Rosenblat, M. Curr. Opin. Lipidol. (2005)
- Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Aviram, M., Kaplan, M., Rosenblat, M., Fuhrman, B. Handb. Exp. Pharmacol (2005)
- Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Aviram, M., Rosenblat, M., Gaitini, D., Nitecki, S., Hoffman, A., Dornfeld, L., Volkova, N., Presser, D., Attias, J., Liker, H., Hayek, T. Clin. Nutr (2004)
- Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. Aviram, M. Free Radic. Biol. Med. (2004)
- Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Aviram, M., Rosenblat, M. Free Radic. Biol. Med. (2004)
- Wine flavonoids protect against LDL oxidation and atherosclerosis. Aviram, M., Fuhrman, B. Ann. N. Y. Acad. Sci. (2002)
- Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Aviram, M., Dornfeld, L., Kaplan, M., Coleman, R., Gaitini, D., Nitecki, S., Hofman, A., Rosenblat, M., Volkova, N., Presser, D., Attias, J., Hayek, T., Fuhrman, B. Drugs. Exp. Clin. Res (2002)
- Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Aviram, M., Dornfeld, L. Atherosclerosis (2001)
- Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Aviram, M., Dornfeld, L., Rosenblat, M., Volkova, N., Kaplan, M., Coleman, R., Hayek, T., Presser, D., Fuhrman, B. Am. J. Clin. Nutr. (2000)
- Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., Rosenblat, M. Circulation (2000)
- Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Aviram, M. Free Radic. Res. (2000)
- Microsomal cytochromes P450 catalyze the oxidation of low density lipoprotein. Aviram, M., Kent, U.M., Hollenberg, P.F. Atherosclerosis (1999)
- Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C.L., Newton, R.S., La Du, B. Free Radic. Biol. Med. (1999)
- Does paraoxonase play a role in susceptibility to cardiovascular disease?. Aviram, M. Mol. Med. Today (1999)
- Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins. Aviram, M. Antioxid. Redox Signal. (1999)
- Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. Aviram, M., Rosenblat, M., Bisgaier, C.L., Newton, R.S., Primo-Parmo, S.L., La Du, B.N. J. Clin. Invest. (1998)
- Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Aviram, M., Rosenblat, M., Bisgaier, C.L., Newton, R.S. Atherosclerosis (1998)
- Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Aviram, M., Fuhrman, B. Atherosclerosis (1998)
- Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogul, J., Hsu, C., Dunlop, C., La Du, B. Arterioscler. Thromb. Vasc. Biol. (1998)
- Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Aviram, M. Eur. J. Clin. Chem. Clin. Biochem (1996)
